Free Information Kit

Learn more about living with lupus and treatment with BENLYSTA

Already taking BENLYSTA?

Get ongoing support for your treatment journey.

Expand to watch videos from
real lupus patients taking BENLYSTA.

Getting Started with BENLYSTA

Ask your doctor if you might be a candidate for treatment with BENLYSTA

  • It is not known if BENLYSTA is safe and effective in people with severe active lupus nephritis or severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations.
  • In 2 of 3 studies, fewer blacks/African Americans who received BENLYSTA responded to treatment compared to blacks/African Americans who did not receive BENLYSTA. Therefore, caution should be used when considering treatment with BENLYSTA in blacks/African Americans. It is important to discuss with your healthcare professional whether BENLYSTA is right for you. A clinical trial is ongoing to study BENLYSTA specifically in blacks/African Americans with lupus.

This is not a full list of the things your healthcare professional will need to consider before prescribing BENLYSTA. For more information, refer to the Medication Guide, and talk to your doctor.

Pregnancy and Breastfeeding

Tell your healthcare professional if you are pregnant or plan to become pregnant. It is not known if BENLYSTA will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with BENLYSTA.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if BENLYSTA passes into your breast milk. You and your healthcare provider should decide if you will receive BENLYSTA or breastfeed. You should not do both.

Women of childbearing age should use adequate birth control measures while taking BENLYSTA and for at least four months after their final treatment with BENLYSTA.

If you become pregnant while receiving BENLYSTA, talk to your healthcare provider about enrolling in the Pregnancy Registry for BENLYSTA. You can enroll in this registry by calling 1-877-681-6296. The purpose of this registry is to monitor the health of you and your baby.

Before taking BENLYSTA

Your healthcare professional is your partner in treating lupus and managing your symptoms. He or she can help you best if you share information regarding your overall health.

Tell your healthcare professional if:

  • You have an infection or have infections that keep coming back. You should not receive BENLYSTA if you have an infection unless your healthcare provider tells you to.
  • You have or have had mental health problems such as depression or thoughts of suicide.
  • You have recently received a vaccination, or think you may need one. If you are receiving BENLYSTA, you should not receive live vaccines.
  • You are allergic to other medicines.
  • You are receiving other biologic medicines, monoclonal antibodies, or IV infusions of cyclophosphamide (Cytoxan). The use of BENLYSTA with these medications is not recommended.
  • You have or have had any type of cancer.

Remember to tell your healthcare professional about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

The Infusion Experience

Morgan, Michelle and Susan describe the infusion process and provide helpful tips for passing the time.

Watch Now

Support for BENLYSTA & Advice for Other Lupus Patients

Michelle, Susan and Morgan talk about the help they got from BENLYSTA® Gateway, and offer words of advice for other people living with lupus.

Watch Now

GSK sponsors ambassadors for BENLYSTA and pays them for their time and expense in sharing their experiences.
Individual results may vary.

What you may experience with BENLYSTA

Be prepared for your infusion and beyond.

Know the risks

Learn more about the potential risks and side effects of BENLYSTA

What Is BENLYSTA?

BENLYSTA is a prescription medication used to treat adults with active systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.

It is not known if BENLYSTA is safe and effective in people with severe active lupus nephritis or severe active central nervous system lupus, and it has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations.

Important Safety Information

The most important information to know about BENLYSTA:

BENLYSTA can cause serious side effects. Some of these side effects may cause death. It is not known if BENLYSTA causes these serious side effects.

Important Safety Information

The most important information to know about BENLYSTA:

BENLYSTA can cause serious side effects. Some of these side effects may cause death. It is not known if BENLYSTA causes these serious side effects.

Tell your healthcare professional right away if you have any of the symptoms listed below while receiving BENLYSTA

Do not receive BENLYSTA if you are allergic to belimumab or to any of the ingredients in BENLYSTA.

Before receiving BENLYSTA also discuss with your healthcare professional if you:

Women of childbearing age should use adequate birth control measures while taking BENLYSTA and for at least four months after their final treatment with BENLYSTA.

Remember to tell your healthcare professional about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Possible side effects of BENLYSTA

The most common side effects of BENLYSTA include:

Tell your healthcare professional if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of BENLYSTA. For more information, ask your healthcare professional.

Other Important Information

In 2 of 3 studies, fewer blacks/African Americans who received BENLYSTA responded to treatment compared to blacks/African Americans who did not receive BENLYSTA. Therefore, caution should be used when considering treatment with BENLYSTA in blacks/African Americans. It is important to discuss with your healthcare professional whether BENLYSTA is right for you. A clinical trial is ongoing to study BENLYSTA specifically in blacks/African Americans with lupus.


For more information, call the BENLYSTA® Gateway at 1-877-4-BENLYSTA (1-877-423-6597)
Monday through Friday, 8 AM to 8 PM Eastern Time.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.